IMUX

Immunic Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 3/10
  • Value↓ 0/10
Immunic sales and earnings growth
IMUX Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 38.00%
  • FCF Y/Y↓ -1.10%
Immunic gross and profit margin trends
IMUX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↑ 675.13%
Immunic net debt vs free cash flow
IMUX Risk
Great
  • Debt / Equity↑ 999.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Immunic stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗